The rest is here:
Basilea reports new prevalence data for EB1, a potential response-predictive biomarker for lisavanbulin in glioblastoma and other tumor types, at ASCO...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh